3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
13
Gynecologic
1
CNS
1
Breast
1
Conditions
Endometrial Neoplasms
19
Ovarian Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Vulvar Neoplasms
2
Thyroid Neoplasms
2
Neoplasm Metastasis
2
Fallopian Tube Neoplasms
2
Advanced Endometrial Cancer
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Ovarian Clear Cell Carcinoma
1
Neoplasms, Glandular and Epithelial
1
Melanoma
1
Liver Neoplasms
1
Interventions
pembrolizumab
6
Nivolumab
3
Cisplatin
3
Carboplatin
3
Paclitaxel
2
Fluorouracil
2
tucatinib
1
pertuzumab
1
milademetan
1
lenvatinib
1
cemiplimab
1
Trastuzumab
1
Tomography, X-Ray Computed
1
Ritonavir
1
Radiation
1
Prednisone
1
Prednisolone
1
Positron-Emission Tomography
1
Pemetrexed
1
Oxaliplatin
1
Magnetic Resonance Imaging
1
Leucovorin
1
Itraconazole
1
Gemcitabine
1
Fulvestrant
1
Cetuximab
1
Capecitabine
1
Brachytherapy
1
Bevacizumab
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
lenvatinib
×
Gynecologic
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts